๐ฅ DeepSeek Asked for $7 Billion. The Checks Came Back at $12 Billion.
DeepSeek went out for about $7 billion and investors came back with at least $12 billion, in a Tencent- and CATL-led round ahead of a planned 2027 IPO.
DeepSeek went out for about $7 billion and investors came back with at least $12 billion, in a Tencent- and CATL-led round ahead of a planned 2027 IPO.
Schneider Electric agreed to buy PTC for $22.6 billion in cash โ a 42.3% premium and its largest acquisition ever. Then its own stock fell 9%. Inside the industrial-software megabet.
Kevin Mandia sold Mandiant to Google for $5.4B. His new startup Armadin just raised $255.5M at a $2.5B valuation to point swarms of AI agents at your own network, before real attackers do.
Instinct, a 23-year-old founder's invite-only AI assistant, raised $1B at a $10B valuation โ 4x its price from a month earlier, with no app and no public user numbers.
Portugal's Tekever just raised $580 million at a $6.4 billion valuation, co-led by the University of California's endowment, on the strength of 50,000 flight hours over Ukraine.
DeepSeek went out for about $7 billion and investors came back with at least $12 billion, in a Tencent- and CATL-led round ahead of a planned 2027 IPO.
๐ฅ Gigabyte Just Dropped a $400 WOLED Gaming Monitor and It Changes Everything...
The AI chip company Cerebras Systems โ the most prominent challenger to Nvidia's GPU empire โ hit the Nasdaq on Thursday under the ticker CBRS and...
> In 2025, startups discovered AI. In 2026, the winners figured out which tools to use and when. Here's the stack the smartest founders are runni...
Bending Spoons is buying Airtable for $1.285 billion in all cash โ about 89% below the productivity startup's $11.7B pandemic-era peak, and its first deal since going public.
The FDA just approved FAYUVI, the first-ever treatment for Sanfilippo syndrome type A: a one-time gene therapy from Ultragenyx priced at $3.95 million per patient.
Adicet's off-the-shelf CAR-T put 54% of a small lupus trial into remission on a single dose. Then the stock dropped 22%.
Precision Neuroscience closed an oversubscribed $250M Series D at a ~$1B valuation, betting its surface brain implant beats drilling into tissue.